Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06912295
PHASE1

Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants

Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

View on ClinicalTrials.gov

Summary

This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.

Official title: A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

76

Start Date

2025-03-21

Completion Date

2025-10-09

Last Updated

2025-08-24

Healthy Volunteers

Yes

Interventions

DRUG

HL-1186

HL-1186 tablet for oral administration.

DRUG

HL-1186 placebo

HL-1186 placebo tablet for oral administration.

Locations (1)

Jiangnan University Affiliated Hospital

Wuxi, China